Patents by Inventor Robert H. BATES

Robert H. BATES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection
    Patent number: 11253500
    Abstract: The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 22, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: David Barros Aguirre, Robert H. Bates, Ruben Gonzalez Del Rio, Alfonso Mendoza Losana, Santiago Ramón García
  • SANFETRINEM OR A SALT OR ESTER THEREOF FOR USE IN TREATING MYCOBACTERIAL INFECTION
    Publication number: 20200289462
    Abstract: The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 17, 2020
    Inventors: David BARROS AGUIRRE, Robert H. BATES, Ruben GONZALEZ DEL RIO, Alfonso MENDOZA LOSANA, Santiago RAMÓN GARCÍA
  • Antituberculosis agent
    Patent number: 10624893
    Abstract: The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: April 21, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Lluis Ballell Pages, David Barros Aguirre, Robert H. Bates, Julia Castro Pichel, Jorge Esquivias Provencio, Kevin Pethe
  • ANTITUBERCULOSIS AGENT
    Publication number: 20190091224
    Abstract: The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 20, 2017
    Publication date: March 28, 2019
    Inventors: Lluis BALLELL PAGES, David BARROS AGUIRRE, Robert H. BATES, Julia CASTRO PICHEL, Jorge ESQUIVIAS PROVENCIO, Kevin PETHE